UCB (EBR:UCB) UCB Media Room: Cimzia China Approval

Transparency directive : regulatory news

22/07/2019 07:00

https://u7061146.ct.sendgrid.net/wf/click?upn=3DG62jSYfZdO-2F12d8lSllQBx1W2= 7HkUdGSImvHQ6Hnxeex7DJ8GmVLDrJamvPVZL3AHMRsbsJRCJcW8MxGRCQWif-2BUZQi5WpxRwX= 4Ooxo84ychDUKro0jR-2BC9pKAMilj-2FS_-2B-2Ft0TnE1oEbVIWS8vHM8JK8eu8RpJ4re5Bwm= FRw6Tr0XlsWOeqQqZTjzwcPKItQR0hTxd9ZQ7rBLYSOuAKeTefElHQ9EZfLoWbvi8z1TsAALNCz= TgTqdBs7Z9NGnROoCyO7AK7gYff6RhVkFhN5EzqoDjvU2l7P8HWBKZw9C7xmcvMRxZMcSX2d7Ug= b6g8eON16BnjT0OCAzIPgfsi-2BcIUMeXGfDcNwVKFJWNB7i9AASGyypAksfVerko8bUwJPZtFz= m6p8UQMg5Xu1ZfMIQlx-2B7LNqWoEbAC4eL6rrdmqN6hqwG283m3afokm99zpFke4uk8XvFzj5B= LAaLRZq5oarbar7yBMB6idAymkp1ZD0-3D ** UCB announces approval of Cimzia=C2=A0in China ------------------------------------------------------------ =C2=B7 After receiving priority review in 2018, CIMZIA=C2=AE (certolizumab = pegol) is now approved in China for the treatment of Moderate-to-Severe Rhe= umatoid Arthritis=C2=A0 =C2=B7 CIMZIA approval in China reinforces UCB=E2=80=99s ongoing commitment= to supporting patient value across China and to offering Chinese patients = innovative medicines to help manage their disease Brussels (Belgium), July 22, 2019 =E2=80=93 07:00 (CET): Belgium-based glob= al bio-pharmaceutical company UCB today announced it has received an Import= Drug License (IDL) from the National Medical Product Administration (NMPA)= , enabling people living with moderate-to-severe rheumatoid arthritis to ac= cess CIMZIA^=C2=AE (certolizumab pegol) in China. This approval provides th= e first biologic therapy in UCB=E2=80=99s portfolio in China, allowing the = company to transition its agile biopharmaceutical model into this important= patient population.=C2=A0 The NMPA granted priority review for the approval of CIMZIA to treat modera= te-to-severe RA in 2018, based on the therapeutic advantage seen with the t= herapy. The submission was based on Phase 3 clinical trial results, RAPID-C= and RAPID-C open-label extension (OLE), which demonstrated efficacy and sa= fety for the approved indication in China. In the 24-week RAPID C study, Ci= mzia in combination with methotrexate showed a rapid onset of response, sus= tained effects in reducing the signs and symptoms of rheumatoid arthritis a= nd improving physical function compared with methotrexate alone with an acc= eptable safety profile in Chinese patients with rheumatoid arthritis and an= inadequate response to methotrexate.^1=C2=A0 =C2=A0UCB also included in th= e submission specific pregnancy and lactation information, based on finding= s from two first-of-their-kind studies in women of childbearing age, CRIB a= nd CRADLE, together with pregnancy outcomes data. The results of the RAPID-C and RAPID-C OLE trials demonstrate the potential= value of CIMZIA for Chinese patients.^2=C2=A0In addition, due to its uniqu= e Fc-free molecular structure, CIMZIA is the only anti-TNF that has evidenc= e from clinical studies from conception to late pregnancy and lactation.^3= =C2=A0 Rheumatoid arthritis is three times more common in women than men. For wome= n patients who have family plans, treatment planning is a key concern. The = approval of Cimzia provides an exciting new choice for those affected by rh= eumatoid arthritis in China, and especially for women of childbearing age,= =E2=80=9D said Professor Li Zhanguo from Peking University People=E2=80=99s= Hospital, Former President of Asia Pacific league of Associations for Rheu= matology, Former Chair of Chinese Rheumatology Association.=C2=A0 =E2=80=9CUCB has a long heritage in rheumatology, with many years of clinic= al experience with CIMZIA in moderate-to-severe rheumatoid arthritis, and w= e are delighted to be bringing a new treatment option to Chinese patients l= iving with this challenging chronic rheumatic condition. This approval is a= lso important for Chinese women who need treatment options to manage their = RA without compromising their plans for pregnancy and breastfeeding,=E2=80= =9D said Emmanuel Caeymaex, Executive Vice President, Immunology Patient Va= lue Unit, UCB. "As a company, UCB is fully dedicated to delivering innovati= ve medicines by connecting our science and research to the needs of patient= s suffering from severe immunological conditions.=E2=80=9D=C2=A0 There are an estimated 5 million patients living with rheumatoid arthritis = in China, with an age-adjusted prevalence of 0.28% (95% CI 0.19%, 0.41%), i= ndicating a need for effective treatment options.^4=C2=A0 =C2=A0=C2=A0 UCB will ensure accelerated patient access to Cimzia=C2=AE through a pionee= ring partnership with Cinkate, a well-established Chinese pharmaceutical co= mpany in rheumatology. The leading digital solutions from Cinkate will help= the alliance to gain patient insights and maximize Physician-Patient inter= action for better disease management. UCB has been present in China since 1996 and has a strong commitment to mak= ing our novel medicines available to support patients living with severe di= seases in the country. UCB=E2=80=99s innovative neurology drugs Neupro and = Vimpat were approved in China in 2018. Additionally, in 2014, UCB inaugurat= ed a new state of the art 13,000 m=C2=B2 manufacturing site in Zhuhai, whic= h strengthened the company=E2=80=99s footprint in the country.=C2=A0 About CIMZIA^=C2=AE in the EU/EEA In the EU, CIMZIA^=C2=AE in combination with methotrexate (MTX) is indicate= d for the treatment of moderate to severe active RA in adult patients inade= quately responsive to disease-modifying anti-rheumatic drugs (DMARDs) inclu= ding MTX.=C2=A0 CIMZIA can be given as monotherapy in case of intolerance to MTX or when co= ntinued treatment with MTX is inappropriate. CIMZIA in combination with MTX= is also indicated for the treatment of severe, active and progressive RA i= n adults not previously treated with MTX or other DMARDs. CIMZIA has been shown to reduce the rate of progression of joint damage as = measured by X-ray and to improve physical function, when given in combinati= on with MTX. CIMZIA, in combination with MTX, is also indicated for the treatment of act= ive psoriatic arthritis in adults when the response to previous DMARD thera= py has been inadequate. CIMZIA can be given as monotherapy in case of intol= erance to MTX or when continued treatment with MTX is inappropriate. CIMZIA is also indicated in the EU for the treatment of adult patients with= severe active axial spondyloarthritis (axSpA), comprising:=C2=A0 =C2=B7 Ankylosing spondylitis (AS) =E2=80=93 adults with severe active AS w= ho have had an inadequate response to, or are intolerant to non-steroidal a= nti-inflammatory drugs (NSAIDs).=C2=A0 =C2=B7 Axial spondyloarthritis (axSpA) without radiographic evidence of AS = =E2=80=93 adults with severe active axSpA without radiographic evidence of = AS but with objective signs of inflammation by elevated C-reactive protein = (CRP) and/or Magnetic Resonance Imaging (MRI) who have had an inadequate re= sponse to, or are intolerant to NSAIDs. CIMZIA is also indicated for the treatment of moderate to severe plaque pso= riasis in adults who are candidates for systemic therapy.=C2=A0 About CIMZIA^=C2=AE in Fertility, Pregnancy and Lactation in the EU/EEA =C2=A0 Women of childbearing potential The use of adequate contraception should be considered for women of childbe= aring potential. For women planning pregnancy, continued contraception may = be considered for 5 months after the last CIMZIA dose due to its eliminatio= n rate, but the need for treatment of the woman should also be taken into a= ccount (see below). =C2=A0 Pregnancy Data from more than 500 prospectively collected pregnancies exposed to CIMZ= IA with known pregnancy outcomes, including more than 400 pregnancies expos= ed during the first trimester, does not indicate a malformative effect of C= IMZIA. However, the available clinical experience is too limited to, with a= reasonable certainty, conclude that there is no increased risk associated = with CIMZIA administration during pregnancy. =C2=A0 Animal studies using a rodent anti-rat TNF=CE=B1 did not reveal evidence of= impaired fertility or harm to the foetus. However, these are insufficient = with respect to human reproductive toxicity. Due to its inhibition of TNF= =CE=B1, CIMZIA administered during pregnancy could affect normal immune res= ponse in the newborn. =C2=A0 CIMZIA should only be used during pregnancy if clinically needed. Non-clini= cal studies suggest low or negligible level of placental transfer of a homo= logue Fab-fragment of certolizumab pegol (no Fc region). =C2=A0 In a clinical study 16 women were treated with certolizumab pegol (200 mg e= very 2 weeks or 400 mg every 4 weeks) during pregnancy. Certolizumab pegol = plasma concentrations measured in 14 infants at birth were Below the Limit = of Quantification (BLQ) in 13 samples; one was 0.042 =C2=B5g/ml with an inf= ant/mother plasma ratio at birth of 0.09%. At Week 4 and Week 8, all infant= concentrations were BLQ. The clinical significance of low levels certolizu= mab pegol for infants is unknown. It is recommended to wait a minimum of 5 = months following the mother's last CIMZIA administration during pregnancy b= efore administration of live or live-attenuated vaccines (e.g. BCG vaccine)= , unless the benefit of the vaccination clearly outweighs the theoretical r= isk of administration of live or live-attenuated vaccines to the infants. =C2=A0 Breastfeeding In a clinical study in 17 lactating women treated with CIMZIA, minimal tran= sfer of certolizumab pegol from plasma to breast milk was observed. The per= centage of the maternal certolizumab pegol dose reaching an infant during a= 24 hour period was estimated to 0.04% to 0.30%. In addition, since certoli= zumab pegol is a protein that is degraded in the gastrointestinal tract aft= er oral administration, the absolute bioavailability is expected to be very= low in a breastfed infant. Consequently, CIMZIA can be used during breastf= eeding. Important Safety Information about CIMZIA^=C2=AE in the EU/EEA=C2=A0 Cimzia^=C2=AE was studied in 4,049 patients with rheumatoid arthritis (RA) = in controlled and open label trials for up to 92 months. The commonly repor= ted adverse reactions (1-10%) in clinical trials with Cimzia=C2=AE =C2=A0an= d post-marketing were viral infections (includes herpeszoster, papillomavir= us, influenza), bacterial infections (including abscess), rash, headache (i= ncluding migraine), asthaenia, leukopaenia (including lymphopaenia, neutrop= aenia), eosinophilic disorder, pain (any sites), pyrexia, sensory abnormali= ties, hypertension, pruritus (any sites), hepatitis (including hepatic enzy= me increase), injection site reactions, and nausea. Serious adverse reactio= ns include sepsis, opportunistic infections, tuberculosis (including miliar= y, disseminated and extrapulmonary), herpes zoster, lymphoma, leukaemia, so= lid organ tumours, angioneurotic oedema, cardiomyopathies (includes heart f= ailure), ischemic coronary artery disorders, pancytopaenia, hypercoagulatio= n (including thrombophlebitis, pulmonary embolism), cerebrovascular acciden= t, vasculitis, hepatitis/hepatopathy (includes cirrhosis), and renal impair= ment/nephropathy (includes nephritis). In RA controlled clinical trials, 4.= 4% of patients discontinued taking Cimzia^=C2=AE due to adverse events vs. = 2.7% for placebo. Cimzia^=C2=AE is contraindicated in patients with hypersensitivity to the a= ctive substance or any of the excipients, active tuberculosis or other seve= re infections such as sepsis or opportunistic infections and moderate to se= vere heart failure. Serious infections including sepsis, tuberculosis and opportunistic infecti= ons (e.g. histoplasmosis, nocardia, candidiasis) have been reported in pati= ents receiving Cimzia^=C2=AE. Some of these events have been fatal. Monitor= patients closely for signs and symptoms of infections including tuberculos= is before, during and after treatment with Cimzia^=C2=AE. Treatment with Ci= mzia must not be initiated in patients with a clinically important active i= nfection. If an infection develops, monitor carefully and stop Cimzia^=C2= =AE until the infection is controlled. Before initiation of therapy with Ci= mzia=C2=AE, all patients must be evaluated for both active and inactive (la= tent) tuberculosis infection. If active tuberculosis is diagnosed prior to = or during treatment, Cimzia^=C2=AE therapy must not be initiated and must b= e discontinued. If latent tuberculosis is diagnosed, appropriate anti-tuber= culosis therapy must be started before initiating treatment with Cimzia=C2= =AE. Patients should be instructed to seek medical advice if signs/symptoms= (e.g. persistent cough, wasting/weight loss, low grade fever, listlessness= ) suggestive of tuberculosis occur during or after therapy with Cimzia=C2= =AE.=C2=A0 Reactivation of hepatitis B has occurred in patients receiving a TNF-antago= nist including Cimzia^=C2=AE who are chronic carriers of the virus (i.e. su= rface antigen positive). Some cases have had a fatal outcome. Patients shou= ld be tested for HBV infection before initiating treatment with Cimzia^=C2= =AE. Carriers of HBV who require treatment with Cimzia^=C2=AE should be clo= sely monitored and in the case of HBV reactivation Cimzia^=C2=AE should be = stopped and effective anti-viral therapy with appropriate supportive treatm= ent should be initiated.=C2=A0 TNF antagonists including Cimzia^=C2=AE may increase the risk of new onset = or exacerbation of clinical symptoms and/or radiographic evidence of demyel= inating disease, including multiple sclerosis; of formation of autoantibodi= es and uncommonly of the development of a lupus-like syndrome; of severe hy= persensitivity reactions. If a patient develops any of these adverse reacti= ons, Cimzia^=C2=AE should be discontinued and appropriate therapy institute= d.=C2=A0 With the current knowledge, a possible risk for the development of lymphoma= s, leukaemia or other malignancies in patients treated with a TNF antagonis= t cannot be excluded. Rare cases of neurological disorders, including seizu= re disorder, neuritis and peripheral neuropathy, have been reported in pati= ents treated with Cimzia^=C2=AE.=C2=A0 Adverse reactions of the haematologic system, including medically significa= nt cytopaenia, have been reported with Cimzia^=C2=AE. Advise all patients t= o seek immediate medical attention if they develop signs and symptoms sugge= stive of blood dyscrasias or infection (e.g., persistent fever, bruising, b= leeding, pallor) while on Cimzia^=C2=AE. Consider discontinuation of Cimzia= =C2=AE therapy in patients with confirmed significant haematological abnorm= alities.=C2=A0 The use of Cimzia^=C2=AE in combination with anakinra or abatacept is not r= ecommended due to a potential increased risk of serious infections. As no d= ata are available, Cimzia^=C2=AE should not be administered concurrently wi= th live vaccines. The 14-day half-life of Cimzia^=C2=AE should be taken int= o consideration if a surgical procedure is planned. A patient who requires = surgery while on Cimzia=C2=AE should be closely monitored for infections.= =C2=A0 Cimzia=C2=AE was studied in 325 patients with active axial spondyloarthriti= s (axSpA) and in 409 patients with psoriatic arthritis (PsA) for up to 4 ye= ars. The safety profile for axSpA and PsA patients treated with Cimzia^=C2= =AE was consistent with the safety profile in RA and previous experience wi= th Cimzia=C2=AE .=C2=A0 Cimzia^=C2=AE was studied in 1112 patients with psoriasis in controlled and= open-label studies for up to 18 months. The safety profile of Cimzia=C2=AE= 400 mg every 2 weeks and Cimzia=C2=AE 200 mg every 2 weeks were generally = similar.=C2=A0 Please consult the full prescribing information in relation to other side e= ffects, full safety and prescribing information. European SmPC date of revi= sion March 2019. https://u7061146.ct.sendgrid.net/wf/click?upn=3DG62jSYfZdO= -2F12d8lSllQB1bgRcJUw8Y6HnHitlehmUp9p23N1ICSEkr9hUTj0vim7zTMmQo26bK8O-2BjuX= 88sB9OJdL3Ci054qpQT9GBqra6-2FDw0ibG27mjCbSf4S7UMr0tZzAfDuNLnfIXchRi4BuA-3D-= 3D_-2B-2Ft0TnE1oEbVIWS8vHM8JK8eu8RpJ4re5BwmFRw6Tr0XlsWOeqQqZTjzwcPKItQR0hTx= d9ZQ7rBLYSOuAKeTefElHQ9EZfLoWbvi8z1TsAALNCzTgTqdBs7Z9NGnROoCyO7AK7gYff6RhVk= FhN5EzqoDjvU2l7P8HWBKZw9C7xmcvMRxZMcSX2d7Ugb6g8eON16BnjT0OCAzIPgfsi-2BcIVA8= wMcjNIkiiT2WnWW1iDkDdSUAVU9m42TlXFdkjMrGn792arGbDP-2FMM450MuXlhjNAZani2u7F4= ZvvAv0qoS-2BLjq1sXpckMtPh5tfGClWfcScZObsaIR0H7-2BWqc2Abg7RdhGZEssSIIXK-2BBB= PIApA-3D CIMZIA^=C2=AE is a registered trademark of the UCB Group of Companies. For further information, UCB: Corporate Communications France Nivelle =C2=A0 Global Communications, UCB T +32.2.559.9178 france.nivelle@ucb.com Laurent Schots=C2=A0 Media Relations, UCB =C2=A0 T+32.2.559.92.64 =C2=A0Laurent.schots@ucb.com=C2=A0 Investor Relations Antje Witte =C2=A0 =C2=A0 =C2=A0 =C2=A0 =C2=A0 Investor Relations, UCB T +32.2.559.94.14 antje.witte@ucb.com Isabelle Ghellynck, =C2=A0Investor Relations, UCB T+32.2.559.9588, isabelle.ghellynck@ucb.com=C2=A0 Brand Communications Andrea Levin Christopher, Immunology Communications, UCB T +1.404.483.7329, andrea.levin@ucb.com=C2=A0 About UCB UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company = focused on the discovery and development of innovative medicines and soluti= ons to transform the lives of people living with severe diseases in immunol= ogy and neurology. With approximately 7 500 people operating in 40 countrie= s, the company generated revenue of =E2=82=AC 4.6 billion in 2018. UCB is l= isted on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news Forward looking statements=C2=A0 This press release contains forward-looking statements based on current pla= ns, estimates and beliefs of management. All statements, other than stateme= nts of historical fact, are statements that could be deemed forward-looking= statements, including estimates of revenues, operating margins, capital ex= penditures, cash, other financial information, expected legal, political, r= egulatory or clinical results and other such estimates and results. By thei= r nature, such forward-looking statements are not guarantees of future perf= ormance and are subject to risks, uncertainties and assumptions which could= cause actual results to differ materially from those that may be implied b= y such forward-looking statements contained in this press release. Importan= t factors that could result in such differences include: changes in general= economic, business and competitive conditions, the inability to obtain nec= essary regulatory approvals or to obtain them on acceptable terms, costs as= sociated with research and development, changes in the prospects for produc= ts in the pipeline or under development by UCB, effects of future judicial = decisions or governmental investigations, product liability claims, challen= ges to patent protection for products or product candidates, changes in law= s or regulations, exchange rate fluctuations, changes or uncertainties in t= ax laws or the administration of such laws and hiring and retention of its = employees.=C2=A0 Additionally, information contained in this document shall not constitute a= n offer to sell or the solicitation of an offer to buy any securities, nor = shall there be any offer, solicitation or sale of securities in any jurisdi= ction in which such offer, solicitation or sale would be unlawful prior to = the registration or qualification under the securities laws of such jurisdi= ction. UCB is providing this information as of the date of this document an= d expressly disclaims any duty to update any information contained in this = press release, either to confirm the actual results or to report a change i= n its expectations. There is no guarantee that new product candidates in the pipeline will prog= ress to product approval or that new indications for existing products will= be developed and approved. Products or potential products which are the su= bject of partnerships, joint ventures or licensing collaborations may be su= bject to differences between the partners. Also, UCB or others could discov= er safety, side effects or manufacturing problems with its products after t= hey are marketed. Moreover, sales may be impacted by international and domestic trends toward= managed care and health care cost containment and the reimbursement polici= es imposed by third-party payers as well as legislation affecting biopharma= ceutical pricing and reimbursement. References: 1.=C2=A0 L. Bi, Y. Li, L. He, H. Xu, Z. Jiang, Y. Wang, X. Li, W. Wei, J. G= u, G. Wang, Z. Zhang, B. Zhou, Y. Liu, Z. Wu, H. Liu, D. He, Z. Lv, Z. Li, = X. Zuo, L. Dong, H. Wu, H. Zhang, H. Chen, C. Bao, Z. Zhang, M. Zhang, H. S= ong, Y. Zheng, L. Jiang, X. Liu, M. Boehnlein, J. Dunkel, J. Shao, K. Harri= s, Z. Li. Clin Exp Rheumatol. 2019; 37(2):227-234. Epub 2018 Aug 29. 2=C2=A0 Bi L, Li Y, He L, Xu H, Gu J, Wang G, Zhang Z, Liu Y, Boehnlein M, = Dunkel J, Shao J, Harris K, Li Z. Rapid Onset of Response Observed with Cer= tolizumab Pegol in Rheumatoid Arthritis Patients with Inadequate Response t= o Methotrexate: Efficacy and Safety Results of a Randomized, Double-Blind, = Placebo-Controlled Phase 3 Study [abstract]. Arthritis Rheumatol. 2017; 69 = (suppl 10) 2.=C2=A0 RAPID-C OLE. Clinical Study Report. Data on File. UCB. 2018. 3.=C2=A0 Mariette X, Forger F, Abraham B, et al. Ann Rheum Dis Published On= line First: 13 October 2017. doi:10.1136/annrheumdis-2017-212196 3.=C2=A0 Clowse ME, F=C3=B6rger F, Hawng C, et al. Minimal to no transfer o= f certolizumab pegol into breast milk: results from CRADLE, a prospective, = postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis. 2017;0:1= =E2=80=937. 4.=C2=A0 Ru Li, Jian Sun, Li-Min Ren, Hong-Yu Wang, Wen-Hong Liu, Xue-Wu Zh= ang, Shi Chen, Rong Mu, Jing He, Yi Zhao, Li Long, Yan-Ying Liu, Xia Liu, X= iao-Lan Lu, Yu-Hui Li, Shi-Yao Wang, Si-Si Pan, Chun Li, Hong-Yuan Wang and= Zhan-Guo Li. Epidemiology of eight common rheumatic diseases in China: a l= arge-scale cross-sectional survey in Beijing. Rheumatology 2012;51:721 729. GenericFile Cimzia China approval press release Final (https://u7061146.ct.sendgrid.net= /wf/click?upn=3DG62jSYfZdO-2F12d8lSllQBx1W27HkUdGSImvHQ6Hnxeex7DJ8GmVLDrJam= vPVZL3Ah3A9VwOy-2BRMRE9-2F9oV3LbDfJJJqwuCqubN9CZXNxzSc-3D_-2B-2Ft0TnE1oEbVI= WS8vHM8JK8eu8RpJ4re5BwmFRw6Tr0XlsWOeqQqZTjzwcPKItQR0hTxd9ZQ7rBLYSOuAKeTefEl= HQ9EZfLoWbvi8z1TsAALNCzTgTqdBs7Z9NGnROoCyO7AK7gYff6RhVkFhN5EzqoDjvU2l7P8HWB= KZw9C7xmcvMRxZMcSX2d7Ugb6g8eON16BnjT0OCAzIPgfsi-2BcIRxglgUiwbknc0ju1aLgueDq= vn2kqrXGFZ7rjdwUiFOX-2B-2BbjXkfIhdIxz3dpKcZA-2FdOtfa0O3pwlzIEaGUjyCsTaQ5evw= AHG96nkXtSIWTx2T9Wx20v-2BWHXa61NJqLkJGW9jhai5PU9dZ27gDLdoer0-3D=0D =0D ______________________=0D If you would rather not receive future communications from UCB SA, please g= o to https://u7061146.ct.sendgrid.net/wf/click?upn=3DG62jSYfZdO-2F12d8lSllQ= Bz2p53T0v-2BoEIvbo6vDi8C-2BOyFzyb6obo-2BzKSgNKq4mrDcczMWCSZc9oJBPWgnvIuIcF5= -2BpNIp1TLdk-2FV-2F2IH7R2nd2aYiRp4Gjfh1214m7hu0ysgDfv4v9bm-2FlnPboESqESb2yR= tT1FP0OlGJcB300-3D_-2B-2Ft0TnE1oEbVIWS8vHM8JK8eu8RpJ4re5BwmFRw6Tr0XlsWOeqQq= ZTjzwcPKItQR0hTxd9ZQ7rBLYSOuAKeTefElHQ9EZfLoWbvi8z1TsAALNCzTgTqdBs7Z9NGnROo= CyO7AK7gYff6RhVkFhN5EzqoDjvU2l7P8HWBKZw9C7xmcvMRxZMcSX2d7Ugb6g8eON16BnjT0OC= AzIPgfsi-2BcIXgkIm-2BYakyESiSa80u4WUkpIpMgLheHAIo0epIHOavDuqjqIxaSu-2BYp0qD= ukR5CUYVvegxpYPQlJeUnGCDgs684Fux02r0u2n2eAtWPPIl30CJXVA3C3LhHUc-2BhuCypKvxg= dtVe1op-2F3QpjoIxWjsM-3D=0D UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium=

UCB's latest news

17/04/2024 07:01

UCB (EBR:UCB) UCB Media Room: Cimzia China Approval

Transparency directive : regulatory news

UCB's latest news

Other stories